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PoultryCoccidiosis is a major intestinal disease affecting economically valuable livestock animals such as chick-
ens and turkeys. Economic losses are associated with decreased productivity in afflicted animals. The dif-
ferent Eimeria spp. are the main etiologic agents for that virulent disease. The usefulness of prophylactic
and therapeutic anticoccidial compounds has decreased in recent years due to the emergence of drug
resistance in Eimeria, together with their possible toxic effect to the human consumers. Despite that,
biosecurity and disinfection measures are the cornerstone to control the emergence of the pathogen,
the immunization methods proved to be more practical and promising to prevent outbreaks due to coc-
cidia. Since the early 1950s, several attempts were followed to formulate commercial immunotherapies,
but up till now none proved to be sufficient. This review summarizes, classifies, and evaluates the trials
performed to prevent avian coccidiosis, thereafter introduces an out of frame scientific strategy to find a
solution for that emerging parasite.
 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Animals as humans, suffer from diseases. Coccidiosis is a
disease that affects a variety of wild type and domesticatedvertebrates including chickens, turkeys, rabbits, cattle, sheep,
goats, pigs, fish, and reptiles. The most virulent and economically
important types of that disease are those infecting poultry and
mammalian livestock. In poultry, the disease usually provokes
severe intestinal disorders, diarrhea, dehydration, loss of weight,
anorexia, and weakness. Therefore, obviously affects the animals
husbandry, due to the reduced production it causes and the
remarked mortality rate [1]. The main etiologic agents of
coccidiosis in poultry are members of the genus Eimeria; which
Table 1
The most important farm animal hosts of Eimeria species.
Host Eimeria spp. References
Chickens E. acervulina, E. brunette, E. necatrix, E. tenella, E.
maxima, E. mitis, E. praecox
[2,3]
Turkeys E. adenoids, E. meleagrimitis, E. dispersa, E.
meleagridis, E. gallopavonis, E. innocua, E. subrotunda
[2]
Rabbits E. stiedae, E. flavescens, E. intestinalis [6]
Cattle E. bovis, E. zuernii, E. alabamensis, E. auburnensis, E.
brasiliensis, E. bukidnonensis, E. canadensis, E.
cylindrica, E. ellipsoidalis, E. pellita, E. subspherica, E.
wyomingensis
[7]
Sheep E. crandallis, E. ovinoidalis, E. faurei, E. granulosa, E.
intricata, E. pallida, E. parva, E. weybridgensis
[7]
Goats E. arloingi, E. christenseni, E. caprina, E. hirci, E.
ninakohlyakimovae, E. alijevi, E. aspheronica, E.
caprovina, E. hirci
[7]
Pigs E. debliecki, E. polita, E. scabra, E. spinosa, E. porci, E.
neodebliecki, E. perminuta, E. suis
[7]
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belong to family Eimeriidae [2]. The clinical disease depends on the
ingested dose of the sporulated oocysts of Eimeria by susceptible
fowl [3]. The different in-host stages of Eimeria spp. invade the cells
of the intestine and duodenum (enterocytes), and replicate result-
ing in variable pathological changes. These changes range from
local destruction of the mucosal barrier and underlying tissue, to
systemic effects such as blood loss, and death [4]. Collectively
those symptoms are associated with drop in egg production,
impaired growth rate due to nutrients malabsorption in adults,
necrotic enteritis due to Clostridium perfringens, and high mortalityFig. 1. (A) Diagrammatic life cycle of Eimeria and (B)rates especially in young’s [5]. Table 1 clusters the different species
of Eimeria in groups according to their domesticated hosts. The
table orders each group from the most virulent to least to that
specific host.
The infection of poultry with Eimeria spp. (Fig. 1) begins when
the host swallows the sporulated oocysts that excyst in the intes-
tine and each releases 8 sporozoites (SZ). Once free within the
intestine, the sporozoites penetrate the host’s enterocyte in very
short time, encapsulate themselves safely within a para-
sitophorous vacuole, and replicate. Merozoites (MZ) are then
released in tremendous numbers, they rupture the host cell, and
invade new ones. It has been proven that each Eimeria sp. is pro-
grammed genetically for a specific number of merogonic divisions.
As much the parasite reinvades the cell, as much it damages the
intestine and causes severe manifestations. After the last species-
specific merogonic generation, merozoites invade the enterocytes
to differentiate into male and female gametocytes (GAM). After fer-
tilization the oocyst ruptures from the host’s enterocytes and
leaves the host with feces [2,8,9].
Experienced farmers noticed that lactating or previously
infected animals show increased survival against the parasite for
several months [10,11]. Despite the loss of an adequate full percep-
tion of immunity against coccidiosis, many studies underlined the
immunological mechanisms that are active during primary and
secondary infection of Eimeria spp. [12]. Hosts usually develop
both immunological specific and nonspecific responses against
the intracellular developmental stages of Eimeria spp. Specific
responses include mucosal and circulating humoral response that
initiates against the sporozoite, the merozoite, and the late sexual
stages [4,13]. On the other hand, the gut-associated lymphoidsimplified structure of Eimeria spp. sporozoite.
Table 2
Overview of the most widely used preventive methods to control coccidiosis.
Strategy Preventive method Effect References
Management and
biosecurity
Disinfection of the materials, the people and
equipments entering the farm
Reduce infection [3]
Oral phytotherapy
and feed
additives
Arteminsin and citric extracts Inhibit the development of Eimeria spp. [35–40]
Oregano, Echinacea, mushrooms (lectin),
turmeric, and betain
Indirectly affect the development of coccidia [3,11,41–
46]
T. violacea antioxidant-rich plant extracts Decreased oocyst production [47]
Lectin (FFrL) extracted from the mushroom
Fomitella fraxinea
Reduction in oocyst shedding [48]
Garlic extract Attenuate inflammation and injury due to liver coccidiosis [49]
Mixture of castor and cashew oils Increase livability of infected animals and reduce intestinal lesions [50]
Prebiotics Mannanoligosaccharides (MOS) ‘BioMos,
SAF-Mannen, Y-Mos, and Celmana’
Block the binding of the pathogens to the mucosal surface
Stimulate the immune response, enhances the development of Bifidobacteria spp.
and Lactobacillus spp., and suppresses the number of enterobacteriacea
[51,52]
Probiotics MitoGrow and MitoMax Lowers intestinal invasion, development of coccidian and oocyst shedding
Increase antibody response
[3,53]
Other products Ibuprofen (non-steroidal anti-inflammatory
drug-NSAID)
Reduces the inflammation due to coccidiosis [54]
Mucolytic enzyme (protease) Impair the attachment of Eimeria to the mucus layer [3]
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CD4+ ab T cell lymphocytes in the cell mediated responses.
Moreover, natural killer (NK) cells appeared to play a main role
in non-specific responses [8,12,14,15].
2. Treatment and drug resistance
Since the 1940s and up till now, more than 30 sulfanilamide
drugs were used for the prophylactic control and treatment of coc-
cidiosis. These anticoccidial products either affect cofactor synthe-
sis, mitochondrial functions, or the cell membrane function of
Eimeria spp. [3]. However, the worldwide use of such drugs led
to the development of lowered efficacy, cross-resistance, and
multi-drug resistance against them all [16]. It was proposed that
the genetic recombination is the major reason underlying the
selection of resistant phenotypes during the development of the
parasite [17].
Meanwhile, the attempt of the rotation of various anticoccidial
drugs in single and/or shuttle programs are followed to diminish
the time for the development of resistance to an extent [18]. In
parallel, solutions for finding new drug targets were studied. In
1998, researchers identified a gene (ets3a) that may be important
in controlling the life cycle of E. tenella [19]. More recently, the iden-
tification of many drug possible targets such as, the enzymes of the
sporozoite mannitol cycle [15,20], the trophozoite histone deacety-
lase, the E. tenella CDC2-related kinase 2 (EtCRK2), and the proto-
zoal cyclic GMP dependent protein kinases, together with the
genes encoding them from Eimeria maxima, paved the way for the
introduction of new anticoccidial products [21]. Simultaneously,
the use of nano-particles was introduced to replace the available
coccidiostats. Although nano-silver did not show a success [22],
nano-zinc was promising against mice’s coccidia [23]. However,
all those solutions are still under trials and Eimeria outbreaks are
still causing harm and economic loss to the animal husbandry.
3. Epidemiology of Eimeria
The spread of coccidiosis disease is a recurrent matter, since
oocysts are carried by both infected and recovered hosts [3]. Over
20 billion broilers are produced globally each year. The US
produces 9 billion broilers alone while Brazil produces around
the same number, with a prevalence of clinical and sub-clinical
coccidiosis that attains 5% and 20%; respectively. The annual cost
sustained by the global poultry industry from the Eimeriainfections has been estimated to be 2.4–3 billion USD, of which
76% is caused by clinical or sub-clinical coccidiosis and 24% by
drug-related costs [2,10,24]. Therefore, the attempts to study and
control Eimeria through epidemiological and environmental factors
flourished.
It was found that the severity of the coccidiosis disease depends
on several factors, such as the facts that some species of Eimeria
showed to be more ‘antigenic’ than others [25]. Although a large
dose of Eimeria spp. oocysts (more than 103) are required to gen-
erate protective immune response, E. maxima requires only a small
number of oocysts to induce almost full immunity. In other species
such as E. tenella, high doses between 15  103 and 45  103 sporo-
zoites, induce complete mortality in chick embryos [26,27].
The second factor that affects the epidemiology of Eimeria is a
cluster of host related ones. Moreover, the clinical signs resulting
from Eimeria infection are significantly influenced by the host’s
genetic factors, since genetically divergent strains show different
levels of susceptibility to coccidiosis [28,29].
Simultaneously, animal husbandry related factors affect the
occurrence of coccidiosis. Poor hygiene of people and equipment,
presence of disease vectors such as rodents and insects in the farm,
and the occurrence of other infectious agents such as viruses and
enteric bacteria collectively affect the spread of the disease and
the severity of the infection [3]. Moreover, it was proven that the
presence of immunized chicks in the litter plays a role in reducing
infection [30,31]. Finally, some environmental factors were shown
to enhance the infection. Although wet litter decreases the sporu-
lated oocyst formation rate for Eimeria, its use to control the spread
was non-practical since the increased humidity was found to cause
footpad lesions and skin burns in animals [3]. In the practical
farm’s life, sanitization as a part of prevention showed to play a
main role in reducing the dissemination of the parasite. However,
new preventive approaches appeared to show some hope to dimin-
ish the emergence of Eimeria outbreaks [2].4. Prevention
The elimination of the source of Eimeria oocysts and continuous
disinfection by anti-oocysts preparation such as ammonium
hydroxide [32], together with the prophylactic chemotherapy are
the corner stone strategies used by most farmers to prevent the
parasite outbreaks. However, substitutes for coccidiosis control
and alternative anticoccidial strategies (Table 2), such as
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vaccination developed [3,33,34].
Although the management and biosecurity measures could
interrupt the introduction of Eimeria spp. to a farm, in practice they
could not stand alone to prevent coccidiosis outbreaks. Moreover,
phytotherapy, aromatherapy, and pre- and pro-biotics show con-
fusing results and have therefore not been applied at large scale
in the field till now [11]. Therefore, practice proved that the most
solid and successful prevention and control strategy for coccidiosis
is immunization [55].5. Passive immunization
The first attempts to passively immunize chickens was in 1988,
when a monoclonal antibody (mAb) raised against the surface anti-
gen (1073.10) of E. tenella sporozoite produced in mice was able to
agglutinate sporozoites in vitro, to lyse the parasite in the presence
of complement, and that the passive transfer of the ammonium
sulfate-precipitated peritoneal ascites fluid was able to protect
against challenge with E. tenella. It was demonstrated as well that
the antiserum raised against the different purified or recombinant
antigens of the different stages of the parasite showed to provide
partial protection [56]. However, studies on recovered chicken sera
taken at IgG peak demonstrated to provide 97% immunity in naive
chicks against homologous challenge [57]. Additionally, it was
found that maternal immunity induced by live infection with E.
maxima can provide partial cross-protection against E. tenella
[58]. Monoclonal antibody raised against the 56-kDa gametocyte
antigen of E. maxima, showed to reduce oocyst shedding after chal-
lenge by 40% in chicks [59]. Simultaneously, monoclonal antibody
raised against the 12-kDa oocyst wall protein of E. tenella was also
found to be capable of providing passive protection [60]. Mean-
while, sonicated gametocytes of E. maxima or its affinity-purified
antigens have demonstrated to confer partial maternal protection
against E. tenella and Eimeria acervulina [13,61].6. Active immunization
Observations in various avian and murine models proved that
even a single infection with oocysts from a given Eimeria sp. can
provoke homologous immunity against reinfection. Therefore, sev-
eral research groups together with the pharmaceutical bodies
introduced to the market a variety of commercial vaccines espe-
cially for poultry [62]. Since killed parasite given by different
routes of vaccination failed to induce protective immunity, the
majority of the commercial ones were live vaccines [4]. Thus, up
till now there are more than 25 commercial anticoccidial vaccines
for use in poultry (Table 3). The following paragraphs classify those
products, together with the research trials in the field.
The effectiveness of live vaccines lies in the oral introduction of
very low doses of the Eimerian oocysts. The ingested living anti-
gens develop and initiate both humoral and cellular responses
against the parasite’s different stages. The robust immune response
against the pathogen protects the host from further infections [15].
The in ovo administration of living oocysts was practiced as a result
of a finding that E. tenella is able to develop in the chick embryo
[63] and allows the 18–19 days old embryo to develop an immu-
nity against the antigenic determinants of the pathogen. However,
the use of asexual subunit vaccines usually enable the immune
system to control a specific stage from the life cycle of Eimeria
[15]. Although immunoglobulins production is a considerable
mechanism to limit the propagation of several pathogens [13],
T-cell mediated response is the major criterion for the control of
intracellular parasites such as Eimeria [8,64,65]. Therefore, the
potency of all vaccines against Eimeria were measured in term ofT-cell lymphocytes activity and by challenge in term of lesion score
(LS), body weight gain (BWG), relative growth rate (RGR), oocysts
decrease rate (ODR), survival rate (SR), and anti-coccidial index
(ACI).
6.1. Live virulent vaccines
Live vaccines group was the first to be studied, due to the fact
that live parasites reduce further reinfection. They comprise para-
sites derived from laboratory or field strains, without any modifi-
cation that changes their natural virulence [63]. The first
commercial live anticoccidial vaccine, CocciVac, was introduced
to the US market in 1952. It comprised a mixture of wild-type
strains of E. tenella oocysts, and conferred a homologous protection
against those strains included in the mixture. Therefore, the vac-
cine went through a number of reformulations over the past 6 dec-
ades and variants of the original product, CocciVac-B, CocciVac-
D and Immucox, are still in use today in more than 40 countries
[63,66]. In parallel live oocysts vaccines proved to be efficient in
turkeys [67]. Recent research focused on the delivery of Eimeria’s
oocysts in gel-beads in day-old chicks [68]. Although vaccination
with wild-type parasites may be very successful, immunovariant
infections within a flock can lead to the emergence of uncovered
strain. This may lead to the ingestion of large numbers of oocysts
by susceptible animals and increases the risk of disease outbreaks
[69]. Therefore, the attenuation of the parasite appeared to over-
come that defect.
6.2. Live attenuated vaccines
These vaccines consist of parasites of artificially reduced viru-
lence as active ingredients. At first, heat treatment and X-
irradiation were used to attenuate Eimeria parasite, but both were
unsuccessful to induce potent preparations. Though, vaccine atten-
uated by irradiation (E. tenella radiovaccine) reported to be a
promising Immunoprophylactic trend against coccidiosis [70,71].
Later on, various methods for the attenuation of the Eimeria para-
site evolved, such as de-routed vaccines of sporozoites and high
doses of merozoites inoculated intra-rectally [72]. However, only
two of these methods have been used to attenuate commercial
vaccines; either by passing parasites through embryonated hens’
eggs (embryo-adapted line) such as Livacox vaccines of E. tenella,
or by selection for precocity (i.e.; the production of parasite strains
that complete their endogenous life cycle in their host faster than
the parent (wild) strains (Table 3). Therefore, they induce immu-
nity without damaging the intestine) such as Livacox and Para-
cox vaccines [63,73].
Practically, embryo-adapted line was difficult to obtain with a
satisfactory combination of immunogenicity and attenuation of
virulence. Moreover, another obstacle that limited embryo-
adaptation as a mean of producing potential vaccination parasites
was the total lack of success in obtaining complete development of
the Eimeria spp. in the embryonic chorio-allantoic membrane. On
the other hand, the method of selection for precocity introduced
by Jeffers in 1975 was the most widely used for the attenuation
of Eimeria parasite in chickens [74]. The unique feature of the
attenuated parasites obtained from the precocious type is the
reduced virulence and pathogenicity of the parasite compared to
the parent strain. Although the production of precocious lines of
all Eimeria species of fowl has been already accomplished, the pro-
duced parasites have lower pathogenicity than the wild ones
[63,75,76]. Therefore, they failed to provide a satisfactory degree
of protective immunity against a heavy challenge. Currently, adju-
vants that consist of different cytokines are paired with the atten-
uated vaccines in order to improve the immunogenicity. However,
economic concerns arose as a limitation [3].
Table 3
First generation vaccines against coccidiosis.*
Vaccine Targeta Speciesb Oocyst
typec
Form Routed Age Concurrent
conditions
Protection Application Last manufacturer
DM coccidiosis Bo Et WT Aq. F 3 d Sulfa drugs NAe 1952–1954 Dorn & Mitchell
(USA)
Coxine Bo Eac, Eh, En, Et WT Aq. Mf 1 d Sulfa drugs NAe 1954–1959 Gland-O-Lac (USA)
NObiCOX Bo Eac, Ema, En, Et WT Aq. Mf 3 d Sulfa drugs NAe 1955–? Nobilis (Netherland)
Coccivac Bo Eac, Ema, En, Et WT Aq. Mf 3 d Sulfa drugs NAe 1955–? Nobilis (Netherland)
MF Coccivac-t/A L Eac, Eh, Ema, En, Et WT Aq. W/Mf – Trithiadol NAe 1959–? Dorn & Mitchell
(USA)MF-Coccivac-t/3 Bo Eac, Eh, Et WT Aq. W/Mf – Trithiadol NAe 1959–1966
MF-Coccivac-t/4 Bo Eac, Ema, En, Et WT Aq. W/Or – Trithiadol NAe 1960–1984
MF-Coccivac-t/B Bd Eac, Eb, Eh, Ema, En, Et WT Aq. W/Or – Trithiadol NAe 1960–1984
MF-Coccivac-t/C L Eac, Eb, Eh, Ema, En, Ep, Et WT Aq. W 10 d Trithiadol NAe 1964–?
MF-Coccivac-t/D L Eac, Eb, Eh, Ema, Emi, En, Ep,
Et
WT Aq. W 10 d Trithiadol NAe 1964–1984
Coccivac-T T Ead, Emel, Eg, Ed WT Aq. W/F/Oc/
H
1–
14 d
(Amprol) 18 week 1984–
present
MSD (UK)
Coccivac-D2 Bo/Bd/
L
Eac, Eb, Ema, Emi, En, Et WT Aq. F/Oc 1–
14 d
– 18 week 1985–
present
Coccivac-B52 Bo Eac, Ema, Emi, Et WT Aq. F/Oc/H 1–
14 d
(Amprol) 18 week 1989–
present
Immunocox-C1/I Bo/R/T Eac, EmaX2, En, Et WT Gel H/W/Or 1–
14 d
– NAe 1985–
present
Vetech (Canada)
Immunocox-C2/II Bd/L Eac, Eb, Ema, En, Et WT Gel H/W/Or 1–
14 d
– NAe 1985–
present
Immunocox-T T Ead, Emel, Eg, Ed WT Gel H/W/Or 1–
14 d
– NAe 1992–
present
Paracox Bo/Bd/
L
Eac, Eb, EmaX2, Emi, En, Ep,
Et
A (P) Aq. H/W/F 1–9 d – 36 week 1989–
present
MSD (UK)
Paracox-5 Bo Eac, EmaX2, Emi, Ep, Et A (P) Aq. H/W/F 1–3 d – 36 week 1989–
present
Paracox-8 Bd/L Eac, EmaX2, Emi, En, Ep, Et A (P) Aq. W/F 1–9 d – 36 week 1989–
present
Livacox-D C Eac, Et A (P, Ea) Aq. W 1–
10 d
– NAe 1992–? Biopharm (Czeck)
Livacox-T Bo Eac, Ema, Et A (P, Ea) Aq. H/W/F 1–
10 d
– NAe 1992–
present
Livacox-Q Bd/L Eac, Ema, En, Et A (P, Ea) Aq. H/W/F 1–
10 d
– NAe 1992–
present
Supercox Bo Eac, Ema, Et(A(P)) WT, A (P) Aq. W 1 d – NAe 1996–
present
Qilu Pharm. (China)
Nobilis-Cox ATM Bo Eac, EmaX2, Et WT/T Aq. H/W/F 1–5 d Ionophores NAe 2001–
present
Intervet/MSD (UK)
Advent Bo Eac, Ema, Et WT Aq. H/W/F 1 d Sulfa drugs NAe 2002–
present
Novus Int. (USA)
HatchpakCocci III Eac, Ema, Et WT Aq. H/W 1 d NAe NAe ?–present Merial/Sanofi (USA)
Vac M Bo Ema (ionopore resistant) WT/T Aq. F/W 1 d Ionophores NAe 1989–
present
Elanco (USA)
Viracox500 Bo Eac, Ema, Ep, Et WT Aq. H/W/F 1–5 d NAe NAe 2001–? Stallen’s (Swiztz.)
Eimerivax 4 m Bd / L Eac, Ema, En, Et A (P) Aq. Oc 1 d – 8 weeks 2003–
present
Bioproperties
(Australia)
Eimerivax 3 m Bo Eac, Ema, Et A (P) Aq. Oc 1 d – 8 Weeks 2003–
present
Immuner Gel-Coc Bo/Bd/
L
Eac, Eb, Ema, Et A (P) Gel Or 1–5 d – NAe 2005–
present
Immuner (Argentina)
Hipracox Bo Eac, Ema, Emi, Ep, Et A (P) Aq. W/Or 1 d – NAe 2006–
present
Hipra (Spain)
Inovocox/TM Bo Eac, EmaX2, Et WT Aq. In ovo – – NAe 2006–
present
Zoetis/Pfizer (USA)
Inovocox-EM1 Bo Eac, Ema, Et WT Aq. In ovo – – NAe 2006–
present
Eimerivac Plus Bd/L Eac, Ema, Emi, En, Et A (P) Aq. W/F 5–
25 d
– NAe 2013–
present
Guandong Acad.
(China)
Eimerivac Plus Bo Eac, Ema, Emi, Et A (P) Aq. W/F 5–
25 d
– NAe 2013–
present
NB. Coccidiosis usually attach 21–28 days old chicks. The vaccines are always applied for healthy chicks or embryonated-eggs (18–19 days old embryo). Aqueous preparation
of the vaccines are formulated with xanthan gum to ensure oocyst homogenous suspension. The immunity is conferred 10–14 days post single dose of vaccination. Chicks are
safe to consume after 21 days for vaccination with WT, while no safety time is necessary for attenuated vaccines. Chicks vaccinated with attenuated vaccines are favored to be
left on the litter to recycle the oocysts. The protection was conferred to chickens along the whole production cycle, unless otherwise specified.
a Target animals: Bd = breeders; Bo = broilers; C = caged chickens; L = layers; R = roasters; T = turkey.
b Eimeria species: Eac = E. acervulina; Ead = E. adenoides; Eb = E. brunetti; Ed = E. dispersa; Eg = E. gallopavonis; Eh = E. hagani; Ema = E. maxima (Ema X2 = two different
serotypes); Emel = E. meleagrimitis; Emi = E. mitis; En = E. necatrix; Ep = E. praecox; Et = E. tenella.
c Oocyte treatment: A = attenuated; Ea = egg adapted; P = attenuated by selection for precocity; WT = wild type virulent living oocyte; WT/T = Live oocyte tolerant to
ionophores.
d Route of administration: F = feed spray; H = colored-spray cabinet on hatchery; Mf = moist feed; Oc = ocular drops; Or = oral; W = water suspension.
e NA = no available data, but it usually refers that the protection is not necessary along the entire broiler cycle.
* Sources of data: ([63,2]; manufacturers’ technical bulletins and internet websites).
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Table 4
Overview of the different antigens used to prepare the subunit and DNA vaccines generations.
Stage Location Eimeria
spp.
Antigen name Type of vaccine, route, adjuvant & %ODR (ACI) Refs.
Protein Recombinant DNA
SZ, MZ SA Et Mzp5-7 – Sc, IM/Vaccinia Virus – [81]
Subcellular enzyme Eac LDH Sc/Quil A/65 Sc/Amphigen/90 OR IM/IB/53
(159)
IM/IFNc, IL2/57
(169)
[18,82,83]
SA Eac Profilin (3-1E) IM/DC/90 Sc/CFA IM [84,85]
TRAP/CSP Et EtMIC1 (Etp100 &
TFP100)
– Sc/IFA/61 – [86,87]
MIC Et EtMIC2 Sc/CFA In ovo/CpG/60-70 OR IM/CFA/85
(180)
IM/70 [88–90]
[91]
TRAP Ema MIC4 (TFP250) – IM/CFA,IFA – [87]
Subcellular structural
protein
Eac a-Tubulin – Sc/CFA/36 – [92]
Soluble MIC Et EtMIC3 Sc/TG-IFA/54 – IM/48.5 [93]
– Eac cSZ-JN1 – Sc/CFA/74.34(161) IM/77.4(169) [94]
SA Et IMP-1 – Sc/FliC, IFA, & TLR-5/88 IM/59.7 [95,96]
SZ RB Et SO7 (RB1 and GX3262) – IM IM/76 (160) [97–100]
GPI-linked SAG Et EtSAG1 (TA4) Sc/CFA Oral in S. typhimurium OR Sc/CFA IM/IL2/75(192) [101–105]
SA Et EtCDPK (pEtk2) – – IM/IL2/70-80 [106]
SA Et AMA-1 – TG-IFA/Sc IM/16 [95]
Rhomboid proteases Et ETRHO1 – IM/CFA,IFA/77.3 – [79]
MZ SA-EAMZp35 Eac p250 – IM/CFA OR oral in E. coli/82 – [107,108]
LDH Eac EaSC2 Sc/Quil A/64 – – [18]
SA Eac Eam45 and Eam20 Sc/Quil A/
65,64
– – [18]
Subcellular enzyme Et GAPDH – Sc/CFA – [109]
GAM WFp Ema GAM56 – IM/CFA IM/53.7 [110,111]
WFp Ema GAM82 – IM/CFA – [110]
MZ/
GAM
Cathepsein-L-like
protease
Et EtCalL – Sc/CFA/86 – [112]
Key: ACI: anti-coccidial index; AMA-1: apical membrane antigen 1; CDPK: calmodulin-domain kinase; CFA: Complete Freund’s Adjuvant; CpG: short oligonucleotide
containing CpG; DC: dendritic cells and heir exposomes; Eac: E. acervulina; EFliC: truncated flagellin; Ema: E. maxima; Et: E. tenella; ETRHO1: rhomboid-like protein; IMP:
immune mapped protein; GAM: gametocyte; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GPI-linked SAGs: glycosylphosphatidylinositol (GPI)-linked surface
antigens (SAGs); IB: inclusion bodies; IFA: Incomplete Freund’s Adjuvant; IM: intra muscular; LDH: lactate dehydrogenase; MIC: microneme (protein); MZ: merozoite; Mzp:
Merozoite protein; NA: not available; ODR: Oocyst Decrease Rate; RB: Refractile Body; SA: surface antigen; Sc: subcutaneous; SZ: sporozoite; TG: Titermax Gold; TLR: toll-like
receptor; TRAP/CSP: thrombospondin-related anonymous protein (TRAP)/circum-sporozoite protein (CSP); WFp: wall forming protein; –: not determined. Gene bank
accesses for the different antigens are provided in their references.
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This strategy depends on co-administering anticoccidial drugs
while the animals are vaccinated by live vaccine strain that tolerate
that drug [73]. Ionophores are the most widely used anticoccidial
drugs for that purpose. They disrupt the trans-membrane ion con-
centration gradients required for the proper functioning and sur-
vival of the parasite. Ionophores act against the susceptible field
parasites prior to the evolvement of the vaccine action, they also
protect against coccidiosis due to species not present in the vac-
cine, and they control necrotic enteritis due to C. perfringens [3,77].
In 1985, Edgar and Fitz-Coy [27] successfully immunized broil-
ers with CocciVac-D during in-feed medication with monensin
ionophore antibiotic. Similarly, Nobilis COX ATM and Vac M vac-
cines (Table 3) depend on other ionophores to enhance the immu-
nity [78]. Unfortunately, the risk of oocysts reverting to a more
pathogenic state, or the variable susceptibility of the host’s genetic
back ground or the resistance toward ionophores chemotherapeu-
tics were safety measures that directed recent researches toward
the different generations of the subunit vaccines to overcome the
risk of the live ones [79].
6.4. Generations of subunit vaccines
These are anticoccidial vaccines composed of distinct protective
antigens, such as micronemes, rhoptries, refractile bodies, mero-
zoites, or gametocytes (Fig. 1B) of Eimeria parasite [1]. They are
either native or recombinant (vectored) subunit second generation
(2nd GN) extracts or DNA (3rd GN) vaccines. CoxAbicwas the firstcommercial subunit vaccine against coccidiosis, which contained a
purified native protein isolated from the gametocytes of E. maxima
(Affinity Purified Gametocyte Antigen; APGA). The vaccine blocks
the transmission of the parasites through inhibiting the develop-
ment of oocysts. However the difficulties associated with antigen
production and the fact that the vaccine only provides an unreli-
able protection (53%) against challenge with Eimeria infections,
limited the advancement of CoxAbic vaccine [59,80].
Likewise, protein antigens of the different asexual stages (Fig. 1)
showed to be more promising as subunit vaccines [113]. These pro-
teins are localized either on the surface of sporozoite or merozoite
stages, or they are secreted by the rhoptries and micronemes dur-
ing the process of invasion (Fig. 1). Among those antigens, dense
granule (DG) proteins are thought to be the key players during
the invasion process. DG antigens are believed to be promising tar-
gets for vaccination since; the contents of DG are deposited in the
parasitophorous vacuole membrane. This means that they are pre-
sent at the actual interface between the parasite and the host’s pro-
teins in the context of major histocompatibility complex molecules
[18,114]. Table 4 summarizes the various antigens that were tested
as subunit recombinant and DNA vaccine candidates. Simultane-
ously, it clarifies the formulation of each preparation, its route of
administration, and potency. It has been reported that the delivery
of recombinant Eimeria antigens using live vectors such as Sal-
monella typhimurium, Fowlpox virus (FPV), or Herpes virus of tur-
keys (HVT) expressing Eimeria DNA sequences is a considerable
approach to protect against coccidiosis [1]. In 2012, a novel
approach using exosome derived from dendritic cells loaded with
Eimeria antigen was tested for vaccination. However, partial
Table 5
Anti-coccidial index of the most promising homologous multi and monovalent T-cell epitopes of Eimeria applied in pVax DNA vaccine preparations [116].
Vaccine preparation Target stage Epitope fragment Eimeria spp. ACI
Quadrivalent/adjuvant SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1-IL-2 En 180.96
Quadrivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1 En 179.17
Trivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2 En 176.92
Quadrivalent/adjuvant SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1-IL-2 Et 175.91
Divalent SZ/SZ NA4-1-TA4-1 En 175.11
Quadrivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1 Et 174.91
Monovalent SZ NA4-1 En 174.77
Trivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2 Et 172.15
Quadrivalent/adjuvant SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1-IL-2 Eac 170.4
Quadrivalent/adjuvant SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1-IL-2 Ema 170.18
Quadrivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1 Ema 169.23
Monovalent SZ EMCDPK-1 Ema 167.18
Divalent SZ/SZ NA4-1-TA4-1 Et 165.91
Monovalent SZ NA4-2 En 165.58
Monovalent SZ TA4-1 Et 165.48
Quadrivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2-EMCDPK-1 Eac 164.34
Trivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2 Eac 164.2
Monovalent MZ LDH-2 Eac 163.72
Monovalent SZ pEtK2-1 Et 163.52
Monovalent SZ/MZ MIC4-2 Et 162.83
Trivalent SZ/SZ/MZ NA4-1-TA4-1-LDH-2 Ema 160.72
Monovalent SZ/MZ MIC4-1 Et 158.34
Divalent SZ/SZ NA4-1-TA4-1 Eac 156.7
Monovalent SZ EMCDPK-1 Ema 155.72
Monovalent SZ pEtK2-2 Et 155.28
Divalent SZ/SZ NA4-1-TA4-1 Ema 154.07
Monovalent SZ/MZ 3-1E-2 Eac 151.8
Monovalent SZ/MZ 5401-1 Et 151
Monovalent MZ LDH-1 Eac 145.79
Monovalent SZ/MZ 3-1E-1 Eac 141.32
Key: 5401: Gene 5401 encoding for a part in EtMIC4; ACI: anti-coccidial index; Eac: E. acervulina; EMCDPK: E. maxima calmodulin-domain protein kinase; Ema: E. maxima; Et:
E. tenella; IL-2: interleukin-2; LDH: lactate dehydrogenase; MIC: microneme protein; MZ: merozoite; NA: sporulated oocyst antigen; pEtK2:; pVax: eukaryotic expression
vector; SZ: sporozoite; TA4: TA4 surface antigen. Gene bank codes are provided in the corresponding reference.
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[115]. Table 4 proposed the importance to use many antigens such
as IMP-1, SO7, ETROH1, p250, EaSC2, and Eam. It highlighted the
special potency of LDH, profiling (3-1E), EtMIC2, MIC4, cSZ-JN1,
EtSAG1 (TA4), EtCDPK (pEtK2), and the EtCalL.
Epitopes mapping of T-cell mediated antigenic determinants
was adopted by Nanjing Agricultural University. In 2015 Song
et al. [116], applied the in silico (DNAStar software) and binding
techniques to investigate several promising epitopes from the
sporozoite and merozoite stages of Eimeria [83,103], and as
concluded from previous research (Table 4). The efficacy of the
epitopes in monovalent and multivalent cloned preparation in
eukaryotic expression vector (pVax) was estimated (Table 5).
The Chinese trials confirmed the remarkable superiority of the
sporozoite’s and merozoite’s antigens over the gametocytes’ to
induce an anticoccidial effect against the pathogen. The research
revealed that the quadri-valent adjuvanted DNA vaccine could
offer an excellent protection of more than ACI-170 for all tested
strains [116]. The multivalent epitope DNA adjuvant-supplied vac-
cine harbored in one plasmid was able to confer a protection
against the major emerging Eimeria species.7. Comment
Eimeria spp. are the major etiologic agents for coccidiosis in
livestock. The disease causes economic loss in farm animals due
to the drop in milk, egg, and meat production, weakness, and the
increment of the chance to induce mortality. The dissemination
of the parasite’s oocysts is feasible, especially in highly productive
crowded farms and readily introduces outbreaks. The routine
infection-control includes the introduction of oocysts-free feed to
the animals, the biosecurity precautions to access the farms,continuous disinfection by potent anti-oocysts preparations, and
the introduction of prophylactic anticoccidial drugs in the animals
feed and drinking water. Despite these strict procedures, coccidio-
sis still affects livestock. Moreover, the concerns regarding drug
residues in animal products increased consumer and governmental
demands to prohibit their use and limited it to control active infec-
tions only [34]. Although anticoccidial chemotherapeutics showed
to be potent for some time, Eimeria spp. developed resistances. This
may render the infection uncontrollable and causes remarkable
economic losses, paving the way toward applying new control
methods [2,3].
Several studies investigated the factors that may reduce the
severity of coccidiosis, but none was practical. Simultaneously,
alternative anticoccidial strategies were evaluated and demon-
strated to be either insufficient or not promising to be used at a
large scale. Until now, all alternatives to prevent coccidiosis infec-
tions were not applicable or outstanding to control outbreaks.
Therefore, since initial infections were able to induce extended
homologous protective immunity, the idea of vaccination against
coccidiosis arose to offer the last promising alternative to win
the battle against that pathogen.
Trials for passive immunization confirmed that antisera raised
against purified antigens only confer partial homologous protec-
tions, while full homologous protection is secured by antisera
raised against the whole stages of the parasite. Additionally they
proved that the antisera raised against gametocytes induce heterol-
ogous maternal immunity. Although these studies highlighted the
unique advantages of the gametocytes proteins, anti-gametocyte
preparations only prevent infected animals from producing infec-
tive oocysts. Therefore, they play a role in limiting the dissemina-
tion of the parasite, but neither treat the infected animal, nor
protect it from further infection. Moreover, the antiserum prepara-
tions are still expensive to be used in the veterinary field.
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developmental stages (Fig. 1A). Therefore, the type of vaccines pro-
duced against those pathogens does not only depend on their
method of preparation, but also on the stage and on the antigen
used to produce that vaccine. The fact that the killed Eimeria spp.
vaccines do not provide protection confirmed that oocysts do not
contain powerful antigenic determinants for the immune system.
However, the observation that the infected animals poses a homol-
ogous protection that lasts for several months, directed the major-
ity of anticoccidial vaccines toward the live ones. Although, the
first vaccine toward Eimeria spp. was composed of live virulent
oocyst preparation, being homologous obliged the vaccinologists
to formulate tri- to heptavalent preparations to cover the most
common strains (Table 2). Although the vaccine showed to be
potent and cheap, the idea of being unable to protect against the
non-included strains, and the emergence of asynchronous out-
breaks was always considered. Since the vaccines were adminis-
tered orally in sub-lethal doses, worries were also attributed to
use it for immuno-compromised animals or those with increased
genetic susceptibility.
The use of attenuated live vaccines, showed to be the solution
for that disquiet and many commercial products are already in
the market for that type. However, the attenuation of the parasite
by heat, X-irradiation or embryo-adapted lines was unsatisfying on
the level of safety and immunogenicity, and therefore paved the
way to the attenuation by precocious protocols. However, the last
one failed to provide a sufficient protection against heavy chal-
lenges, unless formulated with expensive cytokines to improve
its immunogenicity. Moreover, the preparations were unable to
protect from active infections and were not safe enough to use.
Therefore, live vaccines formulated with potent tolerable antic-
occidial drugs, evolved to produce safer therapeutic vaccines.
Those vaccines profited from the privilege of controlling the coc-
cidia species not included in the preparation and the anaerobic
bacterial infections, that deteriorate the cases of infection. How-
ever, the short-time effect and the toxicity of the chemotherapeu-
tics were concerned as limitations. Although several commercial
brands of anticoccidial live vaccines were produced, concerns
about their safety in respect to the host immune state and the par-
asite were always considered.
In the mid-90’s, the idea of preparing native second generation
subunit vaccines from APGA protein of gametocytes was adopted
by a commercial company in Israel. The aim was to produce a fully
safematernal heterologous vaccine against E. maxima. Although the
product was commercialized, difficulties for preparing the antigen
increased its price. However in 2004, the efficiency of a DNA vaccine
based on the wall forming protein (WFp) antigen of the gametocyte
was proved. Despite that GAM-based vaccines prevent oocysts’ for-
mation and dissemination; they also have no effect on protecting
the vaccinated chicks, as has been previously noted. Moreover,
the encapsulated stages showed to be non-immunogenic.
For those reasons the scope was switched toward the use of the
merozoites and sporozoites surface or secreted proteins as vaccine
candidates. Those proteins were produced either by direct extrac-
tion, loaded in delivery vectors, cloned to produce recombinants, or
produced by DNA vaccines in their hosts. The majority of those
effective protein antigens were shared by the merozoites and the
sporozoites stages, while fewer were restricted to one of them.
Simultaneously, the fact that sporozoites presence in the life cycle
of the pathogen is very short for less than 20 min sometimes,
rendered it an elusive target for vaccines and paved the way to
the merozoites-based vaccines. However until recently, none of
the investigated or produced vaccines was enough to confer a
complete safe protection against the pathogen. Unfortunately, only
recent studies started to map the epitopes of some stages of
Eimeria spp. [117,118] to detect the most obvious antigenicdeterminants to the immune system and use them as vaccine
and diagnostic candidates [119]. This was clearly followed by
researchers at the Nanjing Agricultural University in China [94].
They applied in silico and binding epitope mapping techniques to
reveal the most potent heterologous antigenic determinants of
Eimeria [116]. This fact renders more investigation of the most
potent epitope of the Eimeria different stages a target of merit
(Table 4), such as the EtMIC2, cSZ-JN-1, and ETCalL antigens. Those
candidates may be administered in a complex, by a novel immu-
nization regimen. In ovo administration seems to be a promising
route of immunization to ensure the even distribution of the vac-
cine in labor-less method, and ensures a very early protection for
the chicks. This complex should be fully safe, independent on toxic
chemotherapeutics, it should provide a therapeutic effect, reduce
oocyst formation, with a wide spectrum heterologous, maternal,
cheap in production, and should be potent against heavy infections
and outbreaks. The candidates are believed to be used in the form
of DNA vaccines composed of merozoites’ proteins as being
immunologically active immunogens, together with the gameto-
cytes’ proteins that play a main role in reducing the production
and dissemination of oocysts.
Obviously till now all the control products were unable to con-
fer full protection from heavy infection or/and outbreaks. They all
lacked a corner that rendered them ineffective to a certain extent.
This is confirmed by the continuous use of prophylactic anticoc-
cidial drugs till now, regardless of their toxic effect on human con-
sumers. Therefore, the control of coccidiosis in farm animals is
truly an open topic for futuristic investigations. Ideas are open
from the introduction of new control regimens, to researches on
producing genetically resistant hosts.
Furthermore, obviously the agriculture and animal husbandry is
a cultural practice of a specific group of people in a particular
region. Therefore, the experience coming from the trial and error
is affected by the environmental conditions of that area. Since then,
it shall be overlooked case by case. Our observation for the practice
of the Egyptian farmers showed that in case of severe diarrhea for
farm animals, that may be due to coccidia, farmers isolate the ani-
mals and restrict their food to only dry straw while they orally
introduce garlic sap to the infected animals. Farmers also noted
that lactating animals never attain infection at any age, regardless
the mothers previously attained infection or not. This may high-
light the biochemical composition of the mammalian’s milk and
the physiological conditions it induces. Therefore, further scientific
evaluation on those safe environment-attributed cultural practices
should be performed to integrate them to the biosecurity, disinfec-
tion, and vaccination strategies.
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